A pregnant client at 32 weeks gestation is diagnosed with hepatitis B. Which assessment finding would be most concerning to the nurse?

Significantly elevated liver enzymes (ALT 180 U/L, AST 165 U/L) indicate acute hepatic dysfunction and potential liver damage, which poses immediate risks to maternal and fetal health in pregnancy with hepatitis B.

Clinical Reasoning Analysis

The most concerning assessment finding for a pregnant client at 32 weeks gestation with a known hepatitis B infection is elevated liver enzymes (ALT 180 U/L, AST 165 U/L). While a positive HBsAg confirms the chronic carrier state and symptoms like fatigue or dark urine are expected manifestations of hepatitis, a significant transaminase elevation signals active hepatocellular injury. In the context of pregnancy, this finding demands immediate attention not only due to the viral infection itself but because it can be a sentinel sign of superimposed, pregnancy-specific hepatic complications that carry a high risk of maternal and fetal morbidity ^[4].

The physiological changes of pregnancy alter the baseline interpretation of liver function. For instance, alkaline phosphatase rises physiologically due to placental production, while albumin and bilirubin levels typically decrease ^[4]. However, transaminases such as ALT and AST do not undergo significant pregnancy-induced changes. Therefore, a marked elevation to the levels presented here is a definitive indicator of pathology rather than a normal gestational adaptation ^[4]. The nurse must recognize that this degree of hepatocellular damage can rapidly progress. A systematic review on drug-induced liver injury in pregnancy highlights how initially mild symptoms can quickly evolve into fulminant hepatic failure within days, requiring prompt intervention to prevent a fatal outcome ^[1]. Although that review focused on a pharmacological trigger, the clinical trajectory of rapid decompensation from acute hepatocellular injury is a critical concept applicable to any severe hepatic insult during pregnancy.

Furthermore, the differential diagnosis in a pregnant patient with jaundice and elevated transaminases must include conditions unique to gestation, such as intrahepatic cholestasis of pregnancy (ICP). While ICP is classically associated with pruritus and elevated bile acids, emerging research demonstrates that dysregulated metabolic pathways, including iron metabolism, play a role in its pathophysiology ^[2]. This underscores that hepatic disorders in pregnancy are complex and multifactorial. The presence of dark urine and clay-colored stools, while indicative of cholestasis, is a less specific and less immediately ominous finding than a direct marker of ongoing liver cell necrosis. The nurse’s priority is to identify the finding that signals the highest risk for acute clinical deterioration, which is the objective evidence of severe hepatocellular injury reflected in the elevated ALT and AST levels ^[1][4].